OTCMKTS:ARNIArno Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arno Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.0032 0.00 (0.00 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.00Now: $0.00▼$0.0050-Day Range N/A52-Week Range$0.00Now: $0.00▼$0.00Volume3,900 shsAverage Volume71,664 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Arno Therapeutics. Previous Next 2.5 Community Rank Outperform VotesArno Therapeutics has received 50 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArno Therapeutics has received 52 “underperform” votes. (Add your “underperform” vote.)Community SentimentArno Therapeutics has received 50.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arno Therapeutics and other stocks. Vote “Outperform” if you believe ARNI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARNI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArno Therapeutics does not currently pay a dividend.Dividend GrowthArno Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arno Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.50 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARNI Previous Symbol CUSIP042564203 CIK1195116 Webwww.arnothera.com Phone+1-862-7037175Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees4 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable OTC:ARNI Rates by TradingView Receive ARNI News and Ratings via Email Sign-up to receive the latest news and ratings for ARNI and its competitors with MarketBeat's FREE daily newsletter. Arno Therapeutics (OTCMKTS:ARNI) Frequently Asked Questions How has Arno Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Arno Therapeutics' stock was trading at $0.0030 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARNI shares have increased by 6.7% and is now trading at $0.0032. View which stocks have been most impacted by Coronavirus. Has Arno Therapeutics been receiving favorable news coverage? News coverage about ARNI stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arno Therapeutics earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Arno Therapeutics. Who are some of Arno Therapeutics' key competitors? Some companies that are related to Arno Therapeutics include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Apotheca Biosciences (CBDC), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX) and CannaRoyalty (ORHOF). View all competitors. Who are Arno Therapeutics' key executives? Arno Therapeutics' management team includes the following people: Mr. David M. Tanen J.D., Sec. & Director (Age 48) What is Arno Therapeutics' stock symbol? Arno Therapeutics trades on the OTCMKTS under the ticker symbol "ARNI." How do I buy shares of Arno Therapeutics? Shares of ARNI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arno Therapeutics' stock price today? One share of ARNI stock can currently be purchased for approximately $0.00. What is Arno Therapeutics' official website? The official website for Arno Therapeutics is www.arnothera.com. How can I contact Arno Therapeutics? Arno Therapeutics' mailing address is 200 State Route 31 Ste 104, FLEMINGTON, NJ 08822-5812, United States. The company can be reached via phone at +1-862-7037175. This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
